PAIN (Pain AI iNtervention) Platform for Patients at Home
Development of the PAIN (Pain AI iNtervention) Platform for Patients at Home
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Locations
-
-
Florida
-
Jacksonville, Florida, United States, 32224
- Mayo Clinic Florida
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients undergoing low-risk outpatient plastic surgery procedures with expected pain intensities ranging from mild to severe.
Exclusion Criteria:
- Patients with treated or untreated cardiopulmonary syndromes.
- Patients with treated or untreated ophthalmologic pathologies.
- Patients with skin pathologies that prevent us from using the TENS device.
- Patients with pathologies or conditions preventing them from appropriately using their voice.
- Patients with barriers to effective communication.
- Patients with poor digital literacy.
- Patients incapable of taking oral medication.
- Patients who are currently taking medical therapy for chronic pain.
- Patients with a previous diagnosis of severe anxiety disorders.
- Patients who are immobile at baseline.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Post-Surgery data collection system
Subjects undergoing standard of care low-risk plastic surgery be provided with wearable sensors to take home and start recording heart rate, body temperature and body movements
|
Machine learning techniques to rank order physiologic variables obtained via the wearable and handheld devices as well as remove low-importance and redundant variables to accurately determine postoperative pain intensity in outpatients
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Using machine Learning for Postoperative Pain Pain Prediction
Time Frame: 8 months
|
The primary outcome will be the accuracy of machine learning algorithms for postoperative pain prediction using root mean square errors.
|
8 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Physiologic variable %Δ defining the physiologic biomarker's change in measurements after pain medication
Time Frame: 8 months
|
The secondary outcome will be the physiologic variable's use to define the physiologic biomarker's change in measurements after pain medication (%Δ in signal's respective units).
|
8 months
|
|
Physiologic variable absolute Δ defining the physiologic biomarker's change in measurements after pain medication
Time Frame: 8 months
|
The secondary outcome will be the physiologic variable's use to define the physiologic biomarker's change in measurements after pain medication (absolute Δ in signal's respective units).
|
8 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Antonio Forte, MD, PhD, Mayo Clinic
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 21-013443
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.